regulators flagged severe and sometimes fatal pancreatitis cases in 2007-2008 for the earlier GLP-1 drug Byetta (exenatide) and advised clinicians to stop therapy if patients develop persistent severe abdominal pain radiating to the back In the United States, nearly 2,000 GLP-1 lawsuitsprimarily alleging severe gastrointestinal injuries (gastroparesis, bowel obstruction, related complications) after Ozempic, Wegovy, Mounjaro, Trulicity, and other agentsare centralized in federal Multidistrict Litigation (MDL No
The WHO criteria reflect the aim of reducing harmful drinking in those who continue to misuse alcohol
The consequences extend well beyond retailers and manufacturers
Contact your GP or diabetes specialist if you experience : Persistent nausea or vomiting after restarting GLP-1 medication Difficulty maintaining adequate nutrition or hydration Unexplained abdominal pain or bloating Blood glucose levels outside your target range Your healthcare team will provide individualised guidance based on your specific circumstances, ensuring that resumption of GLP-1 therapy supports both your diabetes management goals and surgical recovery
Clinical trials have demonstrated its efficacy, with participants achieving substantial weight loss compared to placebo
